---
document_datetime: 2026-01-28 14:00:04
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8051512
conversion_datetime: 2026-02-01 20:28:48.706403
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zirabev

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000274402 | - -     | 16/10/2025                          | 18/12/2025                                  | SmPC                             | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          | In view of available data on hyaline occlusive glomerular microangiopathy reported in the literature, including in some cases a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing bevacizumab should be amended accordingly.                                                |            |     |                 |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type II / EMA/VR/0000285498    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted | 25/09/2025 | N/A |                 |
| Variation type IA_IN / EMA/VR/0000278463 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                        | 11/09/2025 |     | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000282597   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - Type IB - To update Sections 2, 4.4, 5.1 and 6.1 of the SmPC and Sections 2 and 6 of the PL with information on the excipient polysorbate 80, based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'.                                                                                                                                                                                                                                                                                                                                                                         | 18/07/2025   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                               |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000273197   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update the PI with editorial changes to align with the PI of the reference product. The changes are updates to wording (e.g., spelling, grammar, use of capitalization/hyphenation, minor rewording) and formatting of numbers, ranges, units of measure and storage temperatures throughout the SmPC and PL. The updates include a correction to the wording of a cross-reference within post-marketing ADR | 10/06/2025   | SmPC and PL              | To update the PI with editorial changes to align with the PI of the reference product. The changes follow assessment of the same changes to the reference product Avastin. In addition, the MAH took the opportunity to update the information for the local representative for IE in the PL. |

<div style=\"page-break-after: always\"></div>

|                                       | relocation of the footnotes for Tables 13 and 15 in section 5.1 of the SmPC to the bottom of each table and a minor correction to the wording of a subheading in Table 19 in section 5.1 of the SmPC. The changes follow assessment of the same changes to the reference product Avastin. In addition, the MAH took the opportunity to update the information for the local representative for IE in the PL. Furthermore, the MAH took the opportunity to update to the SmPC and PL to align with QRD template version 10.4, including removal of 'United Kingdom (Northern Ireland)' from the list of local representatives in the PL.   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000254313 | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.c The product is a biological/immunological medicinal product and the change requires an assessment of comparability - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                | 08/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000256400   | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is   | 04/03/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|